References
- . Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256(3):320–332
- . Butterworth RF. Parkinsonism in cirrhosis: Pathogenesis and current therapeutic options. Metab Brain Dis. 2013;28(2):261–267
- . Van Woerkom W. La cirrhose hépatique avec altérations dans les centres nerveux évoluant chez des sujets d'âge moyen. Nouvelle Iconographie de la salpêtriere. Clinique des Maladies du Systeme Nerveux. 1914;7:41–51
- . Wilson SA. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain. 1912;34(4):295–507
- . Klos KJ, Ahlskog JE, Kumar N,. Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology. 2006;67(11):1984–1989
- . Pomier-Layrargues G, Spahr L, Butterworth RF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet. 1995;345(8951):735
- . Meissner W, Tison F. Acquired hepatocerebral degeneration. Handb Clin Neurol. 2011;100:193–197
- . Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: A distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60(4):521–528
- . Couper J. On the effects of black oxide of manganese when inhaled into the lungs. Br Ann Med Pharm Vital Stat Gen Sci. 1837;1:41–42
- . Weissenborn K. Parkinsonism in patients with cirrhosis: Coincidence or consequence? Liver Int. 2011;31(5):592–594
- . Kang JH, Tsai MC, Lin CC, Lin HL, Lin HC. Increased risk of Parkinsonism among patients with cirrhosis: A 7-year follow-up study. Liver Int. 2011;31(5):685–691
- . Tryc AB, Goldbecker A, Berding G,. Cirrhosis-related Parkinsonism: Prevalence, mechanisms and response to treatments. J Hepatol. 2012;58(4):698–705
- . Bergeron M, Reader TA, Layrargues GP, Butterworth RF. Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res. 1989;14(9):853–859
- . Mousseau DD, Baker GB, Butterworth RF. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem. 1997;68(3):1200–1208
- . Weissenborn K, Berding G, Köstler H. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy. Metab Brain Dis. 2000;15(3):173–178
- . Mousseau DD, Perney P, Layrargues GP, Butterworth RF. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett. 1993;162(1–2):192–196
- . Pinarbasi B, Kaymakoglu S, Matur Z,. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible? J Clin Gastroenterol. 2009;43(2):176–181
- . Stracciari A, Baldin E, Cretella L, Delaj L, D'Alessandro R, Guarino M. Chronic acquired hepatocerebral degeneration: Effects of liver transplantation on neurological manifestations. Neurol Sci. 2011;32(3):411–415
- . Ueki Y, Isozaki E, Miyazaki Y,. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration after branched-chain amino acid therapy. Acta Neurol Scand. 2002;106(2):113–116